ProCE Banner Activity

Phase Ib PAVO: Subcutaneous Administration of Coformulated Daratumumab + rHuPH20 in Relapsed/Refractory Myeloma

Slideset Download
Conference Coverage
The use of manual subcutaneous injection of coformulation of daratumumab and rHuPH20 enabled short administration, was well tolerated, and demonstrated a response rate similar to IV daratumumab.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology